Why the Resapp Health Ltd share price is up 1,158% in the past year

A medical technology company: What could be better?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resapp Health Ltd (ASX: RAP) share price has surged another 27% to 23.5 cents in afternoon trading today, and is now up 1,158% since a year ago.

Resapp says it develops digital healthcare solutions to assist doctors and empower patients to self-diagnose and manage respiratory disease. These diseases include pneumonia, asthma, and chronic obstructive pulmonary diseases (COPD) such as emphysema and bronchitis.

Resapp is developing apps to provide instant 'clinical quality' diagnostic tests and management tools.

In what sounds like something from science fiction, the apps basically use the sound of a patient's cough or breathing to diagnose the problem – and don't need any physical contact. It seems smartphones come with such quality microphones – which when combined with Resapp's systems – can diagnose a respiratory disease quickly.

And the market is huge. According to the company, 13.6 million US emergency room visits each year result in a diagnosis of respiratory disease. An estimated 6.3 million Australians suffered from a chronic respiratory condition in 2011-2012 according to the Australian Health Survey.

So far, clinical studies appear highly promising, with the company reporting that in a recent paediatric clinical study, Resapp's diagnostic tool correctly detected 80% of patients initially diagnosed as clear by experienced physicians, but later found to have a lower respiratory tract disease. It also was 99% accurate distinguishing patients with the same disease from those with no discernible disease, and 91% accurate for detecting different types of respiratory tract diseases.

Resapp has also licenced the technology developed by a research team at the University of Queensland, which is a smartphone app (PneumoFone) that provides an instant diagnosis of pneumonia.

The potential is enormous not only with providing a quick and easy diagnosis, but also the ability to capture large amounts of data from hundreds of millions of users around the world, including spread, occurrence and effectiveness of treatment options. That data could then be made available to researchers in various capacities working for the government, at universities, medical research facilities, as well as medical device and pharmaceutical companies.

Foolish takeaway

Even without understanding much about the diseases or the software, many investors can clearly see the benefits of the app, not only to patients and doctors, but the potential to bring in large amounts of revenues for Resapp.

However, there are still major risks ahead, including the potential for another company to develop a better app or process to do the same thing as Resapp's tool as well as regulatory approval. And the company still has to find the best way of commercialising and marketing its product which will be no easy task either.

While I won't be investing just yet, I'll definitely be watching from the sidelines.

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »